NCT04785118View on ClinicalTrials.gov

Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia

PHASE4CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions
Vomiting
Interventions
DRUG

Hyoscine N Butylbromide

Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.

DRUG

Ondansetron

Patients received IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.

DRUG

Saline

Patients received 2 ml of IV normal saline as a placebo just before spinal anaesthesia.

Trial Locations (1)

11111

Assiut University hospital, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT04785118 - Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia | Biotech Hunter | Biotech Hunter